EP 1343501 A4 20041215 - THERAPY FOR HERPES NEUROLOGICAL VIRAL CONDITIONS UTILIZING 1,4-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS
Title (en)
THERAPY FOR HERPES NEUROLOGICAL VIRAL CONDITIONS UTILIZING 1,4-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS
Title (de)
THERAPIE FÜR NEUROLOGISCHE INFEKTIONEN MIT DEM HERPES-VIRUS UNTER VERWENDUNG VON 1,4-DIHYDROPYRIDIN-KALZIUMANTAGONISTEN
Title (fr)
UTILISATION DE BLOQUEURS DU CANAL CALCIUM A LA 1,4-DIHYDROPYRIDINE POUR TRAITER DES ATTEINTES NEUROLOGIQUES IMPUTABLES AU VIRUS DE L'HERPES
Publication
Application
Priority
US 0031994 W 20001121
Abstract (en)
[origin: WO0241893A1] A therapy for Bell's Palsy in mammals is proposed that rests on a causal hypothesis involving both endothelin and the herpes virus, particularly the herpes simplex virus for Bell's Palsy. Similarly, the same therapy would apply to Ramsay Hunt, but in this case the herpes zoster virus would be involved in the causal hypothesis. Other herpes viral related conditions are also suggested to be amenable such as herpes simplex encephalitis. The therapy uses therapeutically effective doses of calcium channel blockers that are of the 1,4-dihydropyridine derivative class, such as felodipine but also including nifedidine, nimodipine, nisodipine or alenodipine. The treatment is proposed as continuing up to the tenth day of progression, but to be started as early as possible. Acyclovir or other herpes antagonists such as famciclovir may also be administered in therapeutically effective dosages.
IPC 1-7
A61K 31/44; A61K 31/50; A61K 31/52; A61K 31/435; A61K 31/445; A61K 31/495
IPC 8 full level
A61K 31/435 (2006.01); A61K 31/44 (2006.01); A61K 31/4422 (2006.01); A61K 31/445 (2006.01); A61K 31/495 (2006.01); A61K 31/50 (2006.01); A61K 31/52 (2006.01); A61K 31/522 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61P 9/00 (2006.01); A61P 25/00 (2006.01); A61P 31/12 (2006.01)
CPC (source: EP)
A61K 31/435 (2013.01); A61K 31/44 (2013.01); A61K 31/445 (2013.01); A61K 31/495 (2013.01); A61K 31/50 (2013.01); A61K 31/52 (2013.01); A61P 9/00 (2017.12); A61P 25/00 (2017.12); A61P 31/12 (2017.12)
Citation (search report)
- [A] US 5039678 A 19910813 - HUTCHINS PHILLIP M [US]
- [A] WO 9414441 A1 19940707 - ASTRA AB [SE]
- [A] LUITEN P G M ET AL: "Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca<2+> antagonist nimodipine, influence of aging and developmental drug treatment", NEURODEGENERATION, ACADEMIC PRESS LTD., LONDON, GB, vol. 4, no. 3, September 1995 (1995-09-01), pages 307 - 314, XP004552087, ISSN: 1055-8330
- See references of WO 0241893A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0241893 A1 20020530; AU 2425001 A 20020603; CN 1479616 A 20040303; EP 1343501 A1 20030917; EP 1343501 A4 20041215; JP 2004513965 A 20040513; NO 20032276 D0 20030520; NO 20032276 L 20030630
DOCDB simple family (application)
US 0031994 W 20001121; AU 2425001 A 20001121; CN 00820124 A 20001121; EP 00987986 A 20001121; JP 2002544071 A 20001121; NO 20032276 A 20030520